FY2025 Earnings Forecast for ELVN Issued By Lifesci Capital

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Equities researchers at Lifesci Capital boosted their FY2025 earnings per share estimates for Enliven Therapeutics in a research report issued on Thursday, May 29th. Lifesci Capital analyst S. Slutsky now forecasts that the company will earn ($2.26) per share for the year, up from their prior estimate of ($2.54). The consensus estimate for Enliven Therapeutics' current full-year earnings is ($1.95) per share.

Several other equities research analysts have also commented on ELVN. HC Wainwright upped their price objective on Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, May 15th. Jones Trading reduced their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a report on Friday, May 16th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $37.25.

Enliven Therapeutics Trading Down 4.1%

ELVN stock traded down $0.92 during midday trading on Monday, reaching $21.37. 579,628 shares of the company's stock traded hands, compared to its average volume of 267,586. Enliven Therapeutics has a 52-week low of $13.30 and a 52-week high of $30.03. The stock has a market cap of $1.05 billion, a P/E ratio of -11.25 and a beta of 1.07. The stock's 50-day moving average is $18.01 and its 200 day moving average is $20.88.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.06).

Institutional Investors Weigh In On Enliven Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its stake in Enliven Therapeutics by 3.5% during the fourth quarter. Invesco Ltd. now owns 15,072 shares of the company's stock valued at $339,000 after acquiring an additional 508 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Enliven Therapeutics by 3.7% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company's stock valued at $451,000 after purchasing an additional 718 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after purchasing an additional 1,114 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Enliven Therapeutics by 14.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company's stock valued at $233,000 after purchasing an additional 1,275 shares in the last quarter. Finally, MetLife Investment Management LLC grew its position in shares of Enliven Therapeutics by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 21,746 shares of the company's stock valued at $489,000 after purchasing an additional 1,285 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $21.44, for a total value of $142,940.48. Following the completion of the sale, the chief operating officer now owns 323,310 shares in the company, valued at approximately $6,931,766.40. This represents a 2.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Joseph P. Lyssikatos sold 7,500 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $20.03, for a total value of $150,225.00. Following the sale, the insider now owns 977,688 shares of the company's stock, valued at $19,583,090.64. This represents a 0.76% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 101,111 shares of company stock worth $1,943,998. Corporate insiders own 29.20% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.